HY

MindWalk Holdings Corp.

HYFTHealthcareNASDAQ

Biotechnology · Last scanned Oct 26, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$15.6M
+46.4% YoY
Net Income
-$13.9M
+53.9% YoY
EBITDA
-$13.9M
+56.7% YoY
Free Cash Flow
$8.8M

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20▼ MACD Negative CrossoverHistogram -0.0137, negative momentum
Oct 19▼ MACD Negative CrossoverHistogram -0.0098, negative momentum
About MindWalk Holdings Corp.

MindWalk Holdings Corp. operates as a bio-native AI company. Valued at $54.6M, HYFT is a micro-cap name in its sector. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology.

Where HYFT stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, HYFT finished 4.35% below its 150-day moving average ($1.38) and 8.97% below its 200-day moving average ($1.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is HYFT overbought or oversold?

At the October 20, 2026 close, HYFT's RSI(14) was 46.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$54.6M
EPS$-0.26
Beta0.78
52W Change-33.0%
Dividend Yield0.00%
ROE-123.7%
Analysis

MindWalk Holdings Corp. holds $7.6M in cash against $3.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $8.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -123.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $20.7M to $15.6M.

With cash comfortably exceeding debt, HYFT has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MindWalk Holdings Corp. and its sector.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms